Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat) in Patients With Refractory Epilepsy

Next Previous
Trial Profile

An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat) in Patients With Refractory Epilepsy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diazepam (Primary) ; Diazepam
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Acorda Therapeutics

Most Recent Events

  • 17 Feb 2017 Status changed from completed to discontinued.
  • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
  • 10 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Jul 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top